Navigation Links
AlphaRx Signs Cooperative Research and Development Agreement with US Army
Date:5/27/2008

MARKHAM, ON, May 27 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to report that AlphaRx and USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases) has entered into a Cooperative Research and Development Agreement for Material Transfer (MTA). The resulting joint R&D effort enables USAMRIID scientists to test the efficacy of AlphaRx's "nanobiotics" for the treatment of severe intracellular bacterial infections caused by Category A pathogens in animal models. Category A pathogens are organisms classified by US Government used mainly in biological weapons that pose a risk to national security.

The MTA covers several "nanobiotics" including Ciprofloxacin, Doxycycline and Gentamicin developed by AlphaRx. These are the usual antibiotics used to treat patients in a bioterrorism event. However, they all show limited efficacy clinically. AlphaRx believes that their specially-formulated version of these antibiotics provides improved intracellular activity in animal studies and may have better clinical efficacy.

AlphaRx is excited with the opportunity to work with the U.S. Army. It opens up a non-commercial application to AlphaRx's drug development programs, with the potential to be a provider to the national stockpile program, through Project Bioshield.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx To Present at 47th Annual ICAAC
2. AlphaRx Announces Debt Conversion
3. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
4. AlphaRx CEO Accumulates More Company Shares
5. AlphaRxs Indaflex(TM) Continues its Clinical Development
6. AlphaRx Provides Corporate and Development Update
7. Pot bellies linked to early signs of cardiovascular disease
8. MSU engineering team designs innovative medical device
9. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
10. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
11. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... Minneapolis MN (PRWEB) , ... February 23, 2017 , ... ... it is sending an expert sit stand solutions representative to the Minneapolis Home and ... 5. Location for the event that is garnering national attention is the Minneapolis Convention ...
(Date:2/22/2017)... ... February 22, 2017 , ... When ... new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. ... healthcare systems recently invested $51 million to purchase and renovate the 185,000 square-foot ...
(Date:2/22/2017)... ... 2017 , ... Stem cell therapy has made significant innovations ... cutting edge, in fact, the U.S. Food and Drug Administration (FDA) has yet ... outcomes in certain clinical stem cell procedures have shown that this revolutionary field ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... WASHINGTON , Feb. 23, 2017  As ... tips.  In addition, the Company is helping people ... through its customized prescription savings programs in all ... Florida Prescription Assistance Program  and  California Prescription Assistance ... tips from Columbia University for nutritious ...
(Date:2/23/2017)... Ga., Feb. 23, 2017  MiMedx Group, Inc. (NASDAQ: ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, ... and full year ended December 31, 2016. ... Revenue is a 31% increase over full year 2015 ...
(Date:2/23/2017)... 2017 LG Innotek today announced that the company has ... its sterilization performance is 1.5 times higher than the competitor,s 45mW ... in the range of 200 -- 280nm, allowing it to be used ... their DNA. LG Innotek,s product emits UV in the range of ... Until now, ...
Breaking Medicine Technology: